3rd Quarter (Apr. to Dec.) of Fiscal Year ending March 2026 Consolidated Financial Results

February 5, 2026

DAICEL CORPORATION

Program

Summary - 3Q (Apr. to Dec.) of FY2026/3 Financial Results

FY2026/3 3Q Result (Y on Y)

Net Sales	424.8 bn yen	(-1.8%)
Operating Income	32.4 bn yen	(-25.0%)
EBITDA	64.0 bn yen	(-12.9%)
Income Attributable to Owners of Parent	35.7 bn yen	(-18.9%)

Exchange Rate USD/JPY: 149 yen
(FY2025/3 3Q USD/JPY: 153 yen)

【Net Sales】Decreased

(+) Sales of airbag inflators increased in the Safety Business, primarily in China and India.

(−) In the Materials Business, acetate tow demand from major customers remained stable, but sales decreased due to inventory adjustments among local customers.

【Operating Income】Decreased

(+) Impact of productivity improvements at the U.S. production site of the Safety business and cost reductions in China.

(−) Impact of carried over inventory from the previous fiscal year in the Materials business and increased depreciation expenses due to the operation of the new plant of Engineering Plastics business.

Summary - 3Q (Apr. to Dec.) of FY2026/3 Financial Results

DAICEL

Progression Rate of Full-year Forecasts

	Full-year forecast*	Progression rate of full-year forecast
Net Sales	583.0 bn yen	(72.9%)
Operating Income	46.5 bn yen	(69.8%)
EBITDA	89.5 bn yen	(71.5%)
Income Attributable to Owners of Parent	50.0 bn yen	(71.4%)

Exchange Rate (forecast) USD/JPY: 146 yen

【3Q Sales Revenue】Fell Short of the Plan* (*Non-disclosed 3Q forecast)

(+) Foreign exchange impact

(+) In the Engineering Plastics business, sales of LCP and PPS exceeded plans, primarily due to strong demand for AI servers. For POM sales, sales volume increased as we strategically lowered prices in the Chinese market while closely monitoring competitors' pricing trends.

(−) Sales timing for acetate tow in the Materials business was postponed to the next fiscal year.

【3Q Operating Income】Exceeded the Plan* (*Non-disclosed 3Q forecast)

(+)Cost reduction effects in the Safety Business and foreign exchange impact

(−) Decrease in sales of acetate tow

【Impact on Full-Year Forecast】

- The CO plant trouble that occurred in January 2026 has been resolved, with operations restarted on January 20, 2026 (financial impact: approx. ¥1.0 billion).
- For the impact of U.S. tariffs on the Safety Business, price pass-through is being implemented as planned with a six-month delay.

*These forecasts were announced on November 6, 2025.

Financial Results

Unit：Billion Yen	25/3 3Q Result	26/3 3Q Result	Y on Y		Full-year Forecast*	Progression Rate of Full-year Forecast*
			Change	%		
Net Sales	432.5	424.8	-7.7	-1.8%	583.0	72.9%
Operating Income	43.2	32.4	-10.8	-25.0%	46.5	69.8%
Ordinary Income	44.8	33.9	-10.9	-24.3%	47.5	71.3%
Profit attributable to owners of parent	44.0	35.7	-8.3	-18.9%	50.0	71.4%
Exchange Rate USD/JPY	153	149				
EBITDA	73.5	64.0	-9.5	-12.9%	89.5	71.5%

*These forecasts were announced on November 6, 2025.

Net Sales and Operating Income by Segment (Y on Y Analysis)

DAICEL

Unit：Billion Yen

	Net Sales							Net Sales
	25/3 3Q Results	26/3 3Q Results	Change	%	Analysis			Progression Rate of Full-year Forecasts*
					Quantity	Prices	Exchange Rate Impact	
Medical / Healthcare	10.9	12.0	+1.2	+10.7%	+1.2	-0.0	-0.3	75.3%
Smart	28.5	27.5	-1.0	-3.5%	-0.4	-0.6	-0.2	70.4%
Safety	72.8	77.0	+4.3	+5.8%	+5.3	-1.1	-0.9	74.4%
Materials	129.2	118.4	-10.8	-8.3%	-2.6	-8.2	-2.2	68.8%
Engineering Plastics	186.8	185.9	-0.9	-0.5%	-0.9	+0.0	-3.1	75.3%
Others	4.4	4.0	-0.4	-9.9%	-0.4	-	-	72.3%
Total	432.5	424.8	-7.7	-1.8%	+2.2	-9.9	-6.7	72.9%

Unit：Billion Yen

	Operating Income								OP
	25/3 3Q Results	26/3 3Q Results	Change	%	Analysis				Progression Rate of Full-year Forecasts*
					Quantity	Prices	Others	Exchange Rate Impact	
Medical / Healthcare	0.4	0.6	+0.3	+75.1%	+1.1	-0.0	-0.8	-0.1	159.8%
Smart	-0.6	0.4	+0.9	-	+0.4	+0.2	+0.3	-0.3	28.6%
Safety	3.1	5.0	+2.0	+64.8%	+2.1	-1.9	+1.8	-0.1	77.4%
Materials	19.1	10.5	-8.6	-45.2%	+4.7	-6.1	-7.3	-1.1	52.3%
Engineering Plastics	20.6	15.3	-5.3	-25.6%	+0.9	+1.9	-8.1	-0.6	87.5%
Others	0.7	0.6	-0.1	-11.2%	-0.1	-	-	-	78.1%
Total	43.2	32.4	-10.8	-25.0%	+9.2	-6.0	-14.0	-2.1	69.8%

*These forecasts were announced on November 6, 2025.

Segment Information – 9 Months (Apr. to Dec.) Results (Y on Y)

Medical / Healthcare

Unit：Billion Yen	25/3 3Q Result	26/3 3Q Result	Y on Y Change	Y on Y %
Net Sales	10.9	12.0	＋1.2	+10.7%
Operating Income	0.4	0.6	+0.3	+75.1%
Exchange Rate USD/JPY	153	149		

Operating Income (YoY)		
Analysis	Change	Main Factors for Operating Income Changes
Quantity	+1.1	Sales volume increased in both Life Sciences and Healthcare
Prices	-0.0	
Others	-0.8	Increased expenses due to increased sales volume and higher research and development cost

【YoY】 Net Sales & OP Up

Life Sciences　Net Sales Up (+1.5%)

Despite a decrease in synthesis service in India, net sales increased due to increased sales volume of chiral columns and sales of stationary phases for pharmaceutical manufacturing in Europe.

Healthcare　Net Sales Up (+36.9%)

The cosmetics and health food markets in Japan and overseas remained strong. Sales of applications for supplements were particularly strong, with significant growth in equol, leading to increased revenue.

Segment Information – 9 Months (Apr. to Dec.) Results (Y on Y)

DAICEL

Smart

Unit：Billion Yen	25/3 3Q Result	26/3 3Q Result	Y on Y	
			Change	%
Net Sales	28.5	27.5	-1.0	-3.5%
Operating Income	-0.6	0.4	+0.9	–
Exchange Rate USD/JPY	153	149		

Operating Income (YoY)		
Analysis	Change	Main Factors for Operating Income Changes
Quantity	+0.4	Increase in sales volume of epoxy resin
Prices	+0.2	Decrease in raw material price
Others	+0.3	Decrease in expenses due to a withdrawal from the organic semiconductor business in December 2024

【YoY】 Net Sales Down ,OP Up

Functional Products Net Sales Up (+0.4%)

Net sales of caprolactone derivatives decreased due to price competition in China and foreign exchange fluctuation.
Net sales of cycloaliphatic epoxies increased due to an expansion in market share, mainly in Europe and the US, and a recovery in demand for electronic materials market particularly for electronic substrates.

Advanced Technology Net Sales Down (-7.8%)

Net sales of solvents for electronic materials increased due to steady semiconductor market trend. Net sales of polymers for photoresists decreased due to timing differences in customer production, despite the positive impact of sales expansion. Net sales of high performance films decreased due to a decrease in sales volume of display film for in-vehicle application, despite a recovery trend in demand for release films for battery applications.

Segment Information – 9 Months (Apr. to Dec.) Results (Y on Y)

DAICEL

Safety

Unit：Billion Yen	25/3 3Q Result	26/3 3Q Result	Y on Y	
			Change	%
Net Sales	72.8	77.0	+4.3	+5.8%
Operating Income	3.1	5.0	+2.0	+64.8%
Exchange Rate USD/JPY	153	149		

Operating Income (YoY)		
Analysis	Change	Main Factors for Operating Income Changes
Quantity	+2.1	Increase in sales volume of inflators
Prices	-1.9	Tariff impact, exchange rate impact
Others	+1.8	Productivity improvement at North American production sites and cost reduction

【YoY】 Net Sales & OP Up

Mobility Net Sales Up (+7.6%)

Although the same period of the previous fiscal year was affected by issues such as the Japanese automobile certification misconduct issue, in the third quarter of the current fiscal year, sales of inflators increased due to factors such as the recovery of production by Chinese automobile manufacturers as a result of government stimulus measures in the Chinese market and the expansion of sales through the addition of new production lines in India.

Industry Net Sales Down (-13.3%)

From the fiscal year ended March 2025, we received orders for new businesses targeting EU and China and expanded sales, but net sales decreased due to a decline in sales of external sales initiators.

Segment Information – 9 Months (Apr. to Dec.) Results (Y on Y)

DAICEL

Materials

Unit：Billion Yen	25/3 3Q Result	26/3 3Q Result	Y on Y Change	Y on Y %
Net Sales	129.2	118.4	-10.8	-8.3%
Operating Income	19.1	10.5	-8.6	-45.2%
Exchange Rate USD/JPY	153	149		

Operating Income (YoY)		
Analysis	Change	Main Factors for Operating Income Changes
Quantity	+4.7	(+) Recovery from the operational issues at the carbon monoxide plant caused in the previous fiscal year (-) Decrease in sales volume of acetate tow
Prices	-6.1	Decline in acetate acid market condition, foreign exchange fluctuation
Others	-7.3	Impact of moving average and increase in expenses of the full acquisition of Toyama Filter Tow, etc.

【YoY】 Net Sales & OP Down

Acetyl Net Sales Down (-9.8%)

Net sales decreased due to a decrease in sales volume of acetate tow resulting from inventory adjustments mainly in local manufacturers, and the impact of foreign exchange rates.

Chemical Net Sales Down (-4.3%)

Sales of cellulose acetate decreased due to a decline in demand for plastics applications in the Chinese market, although the sales volume for LCD applications remained at the same level as the previous fiscal year.
Sales of other products in Chemical business increased due to an increase in sales volume by a recovery of ethyl acetate supply, which had been controlled in the previous fiscal year, and strong demand of 1,3-BG in the cosmetic market.

Segment Information – 9 Months (Apr. to Dec.) Results (Y on Y)

Engineering Plastics

Unit：Billion Yen	25/3 3Q Result	26/3 3Q Result	Y on Y	
			Change	%
Net Sales	**186.8**	**185.9**	**-0.9**	**-0.5%**
Operating Income	**20.6**	**15.3**	**-5.3**	**-25.6%**
Exchange Rate USD/JPY	**153**	**149**		

Operating Income (YoY)		
Analysis	Change	Main Factors for Operating Income Changes
Quantity	+0.9	Increase in sales volume of LCP
Prices	+1.9	Decrease in raw material and fuel price, impact of foreign exchange rate
Others	-8.1	Increase in depreciation expenses and shut-down maintenance cost

【YoY】 Net Sales & OP Down

Polyplastics Co., Ltd. Net Sales Up (+2.0%)

Chinese automotive manufacturers are performing well in China, while Japanese manufacturers are sluggish.
Net sales increased due to a strong sales of LCP, despite foreign exchange fluctuation and a decrease in sales volume of POM.

- Sales volume of POM decreased due to sluggish sales for various industrial sectors resulting from price competition.
- Sales volume of PBT increased due to steady demand for automotive application.
- Sales volume of PPS increased due to strong demand in AI server application, as well as in automotive application.
- Sales volume of LCP increased due to strong demand in AI server application and sharp rise in application for electronic devices such as smartphone and personal computers driven by China's consumer goods trade-in program. The plant in Taiwan, established to expand production capacity started operation in February 2025, reached full-scale operation in May 2025.
- Sales volume of COC remained unchanged due to production adjustment in the previous fiscal year, although demand for eco-friendly packaging materials was sluggish.

Daicel Miraizu Ltd. Net Sales Down (-13.9%)

Net sales of Daicel Miraizu decreased due to the transference the resin compound business to Novacel Co., Ltd. (equity-method affiliate) in July 2024.

Segment Information (Progress on 2nd Half-year Forecasts)

Unit：Billion Yen

		FY2026/3 3Q Result (Oct. to Dec.)	2nd Half-year Forecast*	Progression Rate of 2nd Half-year Forecast*	3Q (Oct. to Dec.) Results VS 3Q Forecast (Not Disclosed)
Medical / Healthcare	Net Sales	4.4	8.4	52.8%	**Net sales exceeded the forecast / Operating income exceeded the forecast** • Regarding Life Sciences business, net sales and operating income exceeded the plan. This was mainly due to strong sales of chiral columns in China, which exceeded the plan, as well as a foreign exchange impact. • Regarding Healthcare business, sales exceeded the plan due to a robust sales of equol, functional food material.
	Operating Income	0.4	0.2	224.5%	
Smart	Net Sales	9.3	20.8	44.6%	**Net sales fell short of the forecast / Operating income exceeded the forecast** • The sales of cycloaliphatic epoxies exceeded the plan due to sales expansion for high value applications. However, the sales of caprolactone derivatives fell short of the plan due to a decline in demand in Europe. • Regarding solvents for electronic materials, the domestic semiconductor market is steady, but sales for LCD panels and sales for automotive paints in Europe fell short of plans. Regarding polymers for photoresists, sales exceeded the plan due to a strong demand of semiconductor. Regarding high-performance films, sales fell short of the plan due to delays in the launch of new products.
	Operating Income	-0.0	0.9	–	
Exchange Rate USD/JPY		154	145		

*These forecasts were announced on November 6, 2025.

Segment Information (Progress on 2nd Half-year Forecasts)

Unit：Billion Yen

		FY2026/3 3Q Result (Oct. to Dec.)	2nd Half-year Forecast*	Progression Rate of 2nd Half-year Forecast*	3Q (Oct. to Dec.) Results VS 3Q Forecast (Not Disclosed)
Safety	Net Sales	27.3	53.8	50.8%	**Net sales exceeded the forecast / Operating income exceeded the forecast** • Net sales exceeded the plan due to an impact of foreign exchange rates, although sales volume of inflators fell short of the plan. Sales Volume was affected by a decrease in production at some automotive manufacturers in the EU market and less-than-expected increase in automotive sales in the market in India, despite strong performance for Chinese automotive manufacturers. • Operating income exceeded the plan due to ongoing cost reductions at all production sites, the of outsourcing logistics operations at the Thailand business site, and the partial passing on increased tariffs to the sales price.
	Operating Income	2.4	3.8	61.8%	
Materials	Net Sales	41.2	94.8	43.5%	**Net sales fell short of the forecast / Operating income fell short of the forecast** • The sales of acetate tow fell short of the plan due to the postponement of purchases by some major tobacco companies and sluggish sales to local tobacco manufacturers.
	Operating Income	5.5	15.0	36.6%	
Engineering Plastics	Net Sales	64.0	125.1	51.2%	**Net sales exceeded the forecast / Operating income exceeded the forecast** • Net sales exceeded the plan due to an increase in sales of PBT for automotive application in Europe. However, sales of COC significantly fell short of the plan due to a slower-than-expected increase in demand for eco-friendly packaging materials. • Operating income exceeded the plan due to an impact of foreign exchange rates.
	Operating Income	3.8	6.0	63.6%	
Exchange Rate USD/JPY		154	145		

*These forecasts were announced on November 6, 2025.

Balance Sheet

Unit：Billion Yen	Mar. 31, 2025	Dec. 31, 2025	Change
Total Current Assets	395.6	421.4	+25.8
Cash and Deposits	65.1	75.8	+10.7
Notes and Accounts Receivable-trade	113.9	116.7	+2.7
Inventories	177.9	184.4	+6.5
Other	38.7	44.5	+5.9
Total Non-Current Assets	418.2	462.6	+44.4
Property, Plant and Equipment	319.4	366.9	+47.5
Intangible Fixed Assets	10.6	11.2	+0.6
Investments and Other Assets	88.1	84.5	-3.7
Total Assets	**813.8**	**884.1**	**+70.3**
Liabilities	438.8	483.9	+45.1
Interest-bearing Liabilities	286.1	326.2	+40.1
Other	152.7	157.7	+5.0
Total Net Assets	375.0	400.2	+25.2
Total Liabilities and Net Assets	**813.8**	**884.1**	**+70.3**
Exchange Rate USD/JPY	**150**	**157**	

- Of the total asset increase, the foreign exchange impact was an increase of 46.4 billion yen.
- Of the 6.5 billion yen increase in inventories, the foreign exchange impact was an increase of 5.7 billion yen. Toward the end of March 2026, we will adjust production of acetate tow in this 4th quarter of FY2026/3 to reduce inventory to a level lower than the end of FY2025/3.
- Property, plant and equipment increased due mainly to an investment for increase in production capacity of POM, LCP and COC in Polyplastics, and an investment for production process conversion of cellulose in Daicel.
- The increase in interest-bearing debt is primarily due to the rise in long-term borrowings related to Polyplastics' production expansion investments in Germany and China.

Revision of Business Plan for Cyclic Olefin Copolymer (COC) and Postponement of Start of Operation for New Plant

Daicel Corporation has decided to review its business plan for cyclic olefin copolymer (COC), which is manufactured and sold by its consolidated subsidiary, TOPAS Advanced Polymers GmbH in Germany, in response to changes in the market environment. We have also decided to postpone the start of operations at the new (second) plant currently under construction.

■ Reason for review of the business plan and postponement of operation of the new plant

We had anticipated a gradual increase in demand for cyclic olefin copolymer (COC) resin, which is widely used in fields such as packaging and healthcare, particularly in the environmentally friendly packaging in Europe starting around 2025. Daicel had been constructing a new (second) COC resin production plant to meet this expected demand. However, following the enforcement of the EU Packaging and Packaging Waste Regulation (PPWR) in February 2025, the market's shift toward environmentally friendly packaging is now progressing with a target of 2030. As a result, the anticipated increase in demand has been slower than originally expected. In addition, the investment for the new plant has increased significantly compared to the initial plan due to the recent surge in construction and labor costs.

Due to these changes in the business environment, there is a significant risk that the profitability of the COC resin business could decline. Therefore, we will reassess future demand trends. Furthermore, considering stable startup and supply-demand balance in operations, the start-up date for the new plant will be postponed from April 2026 to the fourth quarter of the fiscal year ending March 2027.

■ Outlook

We are currently examining the impact on its business plan and its consolidated financial results for the fiscal year ending March 31, 2026, and will promptly make an announcement should any matters requiring disclosure arise.

Cyclic Olefin Copolymer (COC)

【Features and Main Applications】

- COC is a glass-clear and extremely pure amorphous plastics. It has features of excellent moisture barrier, low dissolution and low adsorption, widely used for packaging and medical application.
- COC is used for medical and pharmaceutical packaging, drug delivery, medical equipment, health monitoring device, sustainable packaging (polyolefin (PO) shrink films for PET bottles, PO monomaterial packaging films).

【Net Sales】15.0 billion yen (FY2025/3 Result)

【Sales Volume Forecast】 (VS FY2025/3)

	FY2026/3	FY2027/3
Presentation Materials for FY2025/3 Consolidated Financial Results (Announced on May 13, 2025)	+45%	+50%
As of February 5, 2026	-4%	+32%

Appendix

Shareholders Return

Maintain stable shareholders return in accordance with the following policies; "total return ratio of 40% or more" and "dividend on equity (DOE) ratio of 4% or more"

FY ended March 2025
・**Year-end dividends : 30 yen per share**
(Annual dividends : 60 yen per share: increase by 10 yen from previous fiscal year)
・Purchase of own stocks of 10.98 million shares for 15 billion yen (Period of purchase: from Nov. 2024 to Feb. 2025)

FY ending March 2026
・Interim dividends : 30 yen per share
・Year-end dividends forecasts : 30 yen per share
(Annual dividends forecasts : 60 yen per share: same amount of dividends compared to the previous fiscal year)
・**Decided to purchase treasury stock of 15 billion yen for 11 million shares. (Period of purchase: From Nov. 2025 to Mar. 2026)**

Trends in Income Attributable to Owners of Parent and Dividends in Total Return（Unit: Billion Yen）



Trend in Shareholder Return Indices



Trend in Net Sales, Operating Income, and EPS



*These forecasts were announced on November 6, 2025.

Quarterly Results for Net Sales and Operating Income

Unit：Billion Yen

	Net Sales						
	2025/3				2026/3		
	1Q	2Q	3Q	4Q	1Q	2Q	3Q
Medical / Healthcare	3.5	3.7	3.7	3.6	3.8	3.8	4.4
Smart	10.3	9.3	8.9	8.8	9.5	8.7	9.3
Safety	23.3	23.8	25.7	24.8	24.5	25.3	27.3
Materials	44.5	44.0	40.7	54.2	40.3	36.9	41.2
Engineering Plastics	62.7	61.8	62.3	61.2	59.9	62.0	64.0
Others	1.3	1.6	1.6	1.4	1.3	1.2	1.5
Total	145.6	144.1	142.9	154.0	139.3	137.8	147.7

Unit：Billion Yen

	Operating Income						
	2025/3				2026/3		
	1Q	2Q	3Q	4Q	1Q	2Q	3Q
Medical / Healthcare	0.1	0.1	0.2	-0.1	0.2	0.0	0.4
Smart	0.5	-0.3	-0.8	-0.2	0.2	0.2	-0.0
Safety	-0.0	1.4	1.7	0.9	1.6	1.1	2.4
Materials	9.1	5.3	4.8	10.5	4.4	0.6	5.5
Engineering Plastics	7.7	7.5	5.4	6.4	6.5	4.9	3.8
Others	0.1	0.2	0.4	0.3	0.1	0.3	0.2
Total	17.5	14.1	11.6	17.8	13.0	7.1	12.3

Financial Forecasts (FY ending March 2026)

Unit：Billion Yen	2025/3 Results			2026/3 Revised Forecasts*			Change (B)-(A)
	1st Half (Results)	2nd Half (Results)	Total (A) (Results)	1st Half (Results)	2nd Half (Forecasts)	Total (B) (Forecasts)	
Medical / Healthcare	7.2	7.3	14.4	7.6	8.4	16.0	+1.6
Smart	19.6	17.7	37.3	18.2	20.8	39.0	+1.7
Safety	47.1	50.6	97.6	49.7	53.8	103.5	+5.9
Materials	88.5	94.9	183.4	77.2	94.8	172.0	-11.4
Engineering Plastics	124.5	123.4	248.0	121.9	125.1	247.0	-1.0
Others	2.8	2.9	5.8	2.5	3.0	5.5	-0.3
Net Sales	289.7	296.8	586.5	277.1	305.9	583.0	-3.5
Medical / Healthcare	0.2	0.1	0.3	0.2	0.2	0.4	+0.1
Smart	0.2	-1.0	-0.8	0.4	0.9	1.3	+2.1
Safety	1.3	2.6	3.9	2.7	3.8	6.5	+2.6
Materials	14.3	15.3	29.6	5.0	15.0	20.0	-9.6
Engineering Plastics	15.2	11.8	27.0	11.5	6.0	17.5	-9.5
Others	0.3	0.6	1.0	0.4	0.4	0.8	-0.2
Operating Income	31.6	29.4	61.0	20.1	26.4	46.5	-14.5
Ordinary Income	30.7	31.6	62.3	20.4	27.1	47.5	-14.8
Net Income Attributable to Owners of the Parent	32.1	17.4	49.5	18.8	31.2	50.0	+0.5
(ref.) Exchange Rate USD/JPY	153	152	153	146	145	146	

*These forecasts were announced on November 6, 2025.

Assumptions

		2025/3 (Result)		2026/3 (Previous Forecasts)	2026/3 (Result & Revised Forecasts*)	
		1st Half	2nd Half	Full Year	1st Half (Results)	2nd Half (Forecasts)
Exchange Rate (USD/JPY)		153	152	140	146	145
Raw Materials	Methanol Asian Spot Price (USD/ton)	332	334	330	307	330
	Crude Oil Dubai (USD/bbl.)	82	75	75	69	70
	Domestic Naphtha (JPY/kl)	77,950	74,000	67,000	64,750	63,000

*These forecasts were announced on November 6, 2025.

Main Products List of Each Segment

Segment	Main Business	Main Products
Medical / Healthcare	Life Sciences	Chromatographic columns/stationary phases (chiral columns and achiral columns), Chiral reagents, Seperation servises/purification services, Analytical services, Reagents for genetic analysis research, Novel drug delivery devices
	Healthcare	Cosmetic ingredients (Polyglycerols, Spherical cellulose acetate particles (BELLOCEA®), etc.), Functional food ingredients (Equol, Konjac ceramide, Urolithin, and Lactobionic acid, etc.)
Smart	Functional Products	Cycloaliphatic epoxies, Caprolactone derivatives, Optical lenses
	Advanced Technology	Polymers for photoresists, Solvents for electronic materials, High-performance films
Safety	Mobility	Automobile airbag inflators
	Industry	Pyro-Fuse, Gas generators for seat belt pretensioners (PGG)
Materials	Acetyl	Acetic acid, Acetic anhydride, Acetate tow
	Chemical	Cellulose acetate for optical films (TAC), Cellulose acetate, 1,3-Butylene glycol (1,3-BG), Organic solvents such as Ethyl acetate, Ketene derivatives, Ethylamine
Engineering Plastics	Polyplastics Co., Ltd.	Polyacetal (POM), Polybutylene terephthalate (PBT), Polyphenylene sulfide (PPS), Liquid crystal polymer (LCP), Cyclic olefin copolymer (COC)
	Daicel Miraizu Ltd.	Water-soluble polymers (CMC), Barrier films for packaging and AS resin

Notes Regarding Forward-Looking Statements

- **The purpose of this document is to provide information and not to persuade any individual to take any action in response to the information contained in this document. Daicel has made the greatest possible effort to prepare this document with accurate information. The information in this document, however, may include risks or inaccuracy, and we do not guarantee the accuracy or reliability of this information.**
- **The reader is advised that the use of the information in this document is at your own risk. Any investment according to the prospects, target values, etc. appearing in this document might result in a loss. Daicel accepts no responsibility for such an eventuality.**

This document is an English translation of a statement written originally in Japanese for reference. The Japanese original should be considered as the primary version.